All In Biotech

NDA 021872 · Ucb INC

Keppra

Levetiracetam · Intravenous

Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jul 31, 2006

Approved uses

5

Original approval plus efficacy supplements

Registered trials

261

71 Phase 3, 26 recruiting

FAERS reports

133,531

111,042 serious, 12,023 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2026.

KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) KEPPRA is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy ( 1.2 ) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy ( 1.3 ) KEPPRA injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible ( 1.4 ) 1.1 Partial-Onset Seizures KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy KEPPRA is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures KEPPRA is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. 1.4 Limitations of Use KEPPRA injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.

Mechanism: The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • KEPPRA · LEVETIRACETAM 500MG/5ML (100MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Levetiracetam" as an intervention, any sponsor and status, largest first.

All 261 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure15,769
  • drug ineffective12,490
  • off label use9,614
  • fatigue5,592
  • somnolence4,201
  • epilepsy4,178
  • convulsion3,988
  • maternal exposure during pregnancy3,813
  • fall3,746
  • headache3,723
  • nausea3,627
  • dizziness3,594

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004515
2005758
2006908
20071,182
20081,355
20092,201
20102,447
20113,020
20123,954
20134,020
20144,593
20156,309
20168,121
20177,640
201810,346
201911,939
20209,879
202110,064
20228,884
20239,509
20249,901
20258,886
20267,096

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Keppra* (Levetiracetam)

2024 spending

$71.7M

Beneficiaries

5,281

37,683 claims

Per beneficiary

$13,576

$12.26 per unit

View as table
YearSpending
2020$77,825,801
2021$75,185,539
2022$76,701,477
2023$76,290,254
2024$71,692,904

Part B: Keppra* (Levetiracetam*) · HCPCS J1953

2024 spending

$3K

Beneficiaries

135

324 claims

Per beneficiary

$21

2024 ASP limit $0.06 per unit

View as table
YearSpending
2020$4,336
2021$2,716
2022$3,121
2023$2,832
2024$2,802

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 773 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.